-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
*Only for medical professionals to read and refer to the wonderful review of the new GLP-1RA launch meeting-global treatment experience sharing, to understand which patients are suitable for clinical treatment "rising star"
.
Glucagon-like peptide-1 receptor agonist (GLP-1RA) is a hot spot in the research and development of hypoglycemic drugs in recent years
.
Smeglutide, which has just been marketed in China, belongs to GLP-1RA weekly preparations, which takes into account the comprehensive benefits of potent hypoglycemic and cardiovascular metabolism
.
At present, two indications have been approved in China: it is suitable for adults with type 2 diabetes (T2DM) who have poor blood glucose control after receiving metformin and/or sulfonylureas on the basis of diet control and exercise; The risk of major cardiovascular adverse events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adult T2DM patients with cardiovascular disease
.
In the third video, we will use Professor Yale from Canada and Professor Yu Miao from Peking Union Medical College Hospital to learn about Professor Yale’s clinical experience in using smeglutide.
Let’s take a look! Keywords: strong blood glucose management, multiple benefits, wide clinical applicability
.
Case 1 is a 63-year-old bus driver, hemoglobin glycosylated (HbA1c) 7.
4%, body mass index (BMI) 25.
4kg/m2, the goal is to reduce blood sugar while appropriately losing weight
.
SUSTAIN series of studies suggest that simeglutide can significantly reduce HbA1c in patients with T2DM by 1.
8%, which is significantly better than sitagliptin, exenatide weekly preparations, dulaglutide, canagliflozin, liraglutide, As well as various positive controls such as insulin glargine, the risk of hypoglycemia is extremely low
.
Professor Yale pointed out that simeglutide can reduce blood sugar on demand.
The higher the baseline HbA1c, the greater the decrease in HbA1c.
For example, when the baseline HbA1c is 9.
5%, the decrease can reach 2.
5%; when the baseline HbA1c is close to the normal value, such as 7.
4%, The decrease in HbA1c is relatively small, but it is also about 1%, which is better than many other hypoglycemic drugs
.
It can be said that smeglutide helps patients better meet the standard without paying the price of hypoglycemia
.
In addition, smeglutide can also lose weight on demand, which is suitable for patients with different baseline BMI
.
In the end, the patient chose to use smeglutide 0.
5mg for treatment, and the desired effect was achieved
.
Case 2 is a 68-year-old female, university teacher, HbA1c6.
6%, has repeated episodes of hypoglycemia, BMI 26.
5kg/m2, and has a history of cardiovascular disease.
Therefore, it is urgent to solve the problem of hypoglycemia, reduce weight and optimize cardiovascular disease Protection
.
The cardiovascular outcome trial of smeglutide-SUSTAIN 6 results showed that among patients with high cardiovascular risk of T2DM, the risk of major cardiovascular adverse events (MACE) in patients receiving smeglutide was significantly higher than that of the placebo group Reduced by 26%, the risk of non-fatal stroke was reduced by 39%
.
The cardiovascular benefits of 0.
5mg are similar to those of 1.
0mg
.
In the end, the patient used sodium-glucose cotransporter 2 inhibitor (SGLT-2i), combined with 1.
0 mg smeglutide, and stopped using sulfonylureas and dipeptidyl peptidase 4 inhibitors (DPP-4i).
), finally achieved the desired effect
.
Application skills The gastrointestinal adverse reactions of smeglutide are transient
.
Clinically, a small dose (0.
25 mg) can be started, and subsequent adjustments can be made according to the patient's condition to reduce gastrointestinal side effects
.
Afterwards, Professor Yale and the Chinese experts also expressed their opinions on the applicable people and usage skills of smegaglutide in online audiences, and had a wonderful discussion.
.
.
If you want to know more, remember to check the full video! -End-"This article is only used to provide scientific information to medical and health professionals, and does not represent the platform's position" for submission/reprint/business cooperation, please contact: pengsanmei@yxj.
org.
cn
.
Glucagon-like peptide-1 receptor agonist (GLP-1RA) is a hot spot in the research and development of hypoglycemic drugs in recent years
.
Smeglutide, which has just been marketed in China, belongs to GLP-1RA weekly preparations, which takes into account the comprehensive benefits of potent hypoglycemic and cardiovascular metabolism
.
At present, two indications have been approved in China: it is suitable for adults with type 2 diabetes (T2DM) who have poor blood glucose control after receiving metformin and/or sulfonylureas on the basis of diet control and exercise; The risk of major cardiovascular adverse events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adult T2DM patients with cardiovascular disease
.
In the third video, we will use Professor Yale from Canada and Professor Yu Miao from Peking Union Medical College Hospital to learn about Professor Yale’s clinical experience in using smeglutide.
Let’s take a look! Keywords: strong blood glucose management, multiple benefits, wide clinical applicability
.
Case 1 is a 63-year-old bus driver, hemoglobin glycosylated (HbA1c) 7.
4%, body mass index (BMI) 25.
4kg/m2, the goal is to reduce blood sugar while appropriately losing weight
.
SUSTAIN series of studies suggest that simeglutide can significantly reduce HbA1c in patients with T2DM by 1.
8%, which is significantly better than sitagliptin, exenatide weekly preparations, dulaglutide, canagliflozin, liraglutide, As well as various positive controls such as insulin glargine, the risk of hypoglycemia is extremely low
.
Professor Yale pointed out that simeglutide can reduce blood sugar on demand.
The higher the baseline HbA1c, the greater the decrease in HbA1c.
For example, when the baseline HbA1c is 9.
5%, the decrease can reach 2.
5%; when the baseline HbA1c is close to the normal value, such as 7.
4%, The decrease in HbA1c is relatively small, but it is also about 1%, which is better than many other hypoglycemic drugs
.
It can be said that smeglutide helps patients better meet the standard without paying the price of hypoglycemia
.
In addition, smeglutide can also lose weight on demand, which is suitable for patients with different baseline BMI
.
In the end, the patient chose to use smeglutide 0.
5mg for treatment, and the desired effect was achieved
.
Case 2 is a 68-year-old female, university teacher, HbA1c6.
6%, has repeated episodes of hypoglycemia, BMI 26.
5kg/m2, and has a history of cardiovascular disease.
Therefore, it is urgent to solve the problem of hypoglycemia, reduce weight and optimize cardiovascular disease Protection
.
The cardiovascular outcome trial of smeglutide-SUSTAIN 6 results showed that among patients with high cardiovascular risk of T2DM, the risk of major cardiovascular adverse events (MACE) in patients receiving smeglutide was significantly higher than that of the placebo group Reduced by 26%, the risk of non-fatal stroke was reduced by 39%
.
The cardiovascular benefits of 0.
5mg are similar to those of 1.
0mg
.
In the end, the patient used sodium-glucose cotransporter 2 inhibitor (SGLT-2i), combined with 1.
0 mg smeglutide, and stopped using sulfonylureas and dipeptidyl peptidase 4 inhibitors (DPP-4i).
), finally achieved the desired effect
.
Application skills The gastrointestinal adverse reactions of smeglutide are transient
.
Clinically, a small dose (0.
25 mg) can be started, and subsequent adjustments can be made according to the patient's condition to reduce gastrointestinal side effects
.
Afterwards, Professor Yale and the Chinese experts also expressed their opinions on the applicable people and usage skills of smegaglutide in online audiences, and had a wonderful discussion.
.
.
If you want to know more, remember to check the full video! -End-"This article is only used to provide scientific information to medical and health professionals, and does not represent the platform's position" for submission/reprint/business cooperation, please contact: pengsanmei@yxj.
org.
cn
